CA3069016A1 - Bicyclic urea kinase inhibitors and uses thereof - Google Patents

Bicyclic urea kinase inhibitors and uses thereof Download PDF

Info

Publication number
CA3069016A1
CA3069016A1 CA3069016A CA3069016A CA3069016A1 CA 3069016 A1 CA3069016 A1 CA 3069016A1 CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A1 CA3069016 A1 CA 3069016A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069016A
Other languages
English (en)
French (fr)
Inventor
Nathanael S. Gray
Yanke Liang
Hwan Geun Choi
Thomas Sundberg
Alykhan Shamji
Ramnik Xavier
David E. Fisher
Nisma MUJAHID
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical General Hospital Corp
Priority to CA3293479A priority Critical patent/CA3293479A1/en
Publication of CA3069016A1 publication Critical patent/CA3069016A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA3069016A 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof Pending CA3069016A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3293479A CA3293479A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358524P 2016-07-05 2016-07-05
US62/358,524 2016-07-05
PCT/US2017/040722 WO2018009544A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3293479A Division CA3293479A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3069016A1 true CA3069016A1 (en) 2018-01-11

Family

ID=59351134

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3069016A Pending CA3069016A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof
CA3293479A Pending CA3293479A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3293479A Pending CA3293479A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Country Status (10)

Country Link
US (4) US10954242B2 (enExample)
EP (2) EP3481830B1 (enExample)
JP (1) JP7277357B2 (enExample)
KR (1) KR20190075043A (enExample)
CN (1) CN110225914A (enExample)
AU (1) AU2017291812B2 (enExample)
CA (2) CA3069016A1 (enExample)
ES (1) ES2920823T3 (enExample)
IL (1) IL264106B (enExample)
WO (1) WO2018009544A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
BR112019017741A2 (pt) * 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
AU2019243289B2 (en) * 2018-03-30 2023-01-12 Les Laboratoires Servier Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
EP3831409A4 (en) * 2018-08-01 2022-05-11 ONO Pharmaceutical Co., Ltd. Therapeutic agent for cartilage disease
US20230027026A1 (en) * 2019-09-27 2023-01-26 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN115916966A (zh) * 2020-01-30 2023-04-04 加利福尼亚大学董事会 Strad结合剂及其用途
AU2021262482A1 (en) * 2020-04-28 2023-01-05 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
US12428422B2 (en) 2020-05-14 2025-09-30 Rhizen Pharmaceuticals Ag Purine derivatives as SIK-3 inhibitors
US12590098B2 (en) 2020-09-16 2026-03-31 Axceso Biopharma Co., Ltd. Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same
US20230265099A1 (en) * 2020-09-21 2023-08-24 Soltego, Inc. Sik inhibitors and methods of use thereof
CN116801878A (zh) * 2020-10-05 2023-09-22 达纳-法伯癌症研究所股份有限公司 Her2的有效和选择性抑制剂
US20240124464A1 (en) * 2020-12-02 2024-04-18 Impact Therapeutics (Shanghai), Inc Substituted fused bicyclic compound as kinase inhibitor and use thereof
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN117547615B (zh) * 2023-09-26 2024-12-06 首都医科大学宣武医院 一种纳米囊泡及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
CN1150195C (zh) 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
AU2003225161A1 (en) 2002-04-24 2003-11-10 Koo, Han-Mo Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
AU2003257633A1 (en) 2002-08-21 2004-03-11 Mitsuhiro Okamoto Salt-inducible kinases 2 and use thereof
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
JP2006522756A (ja) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2008510690A (ja) 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
CA2610598A1 (en) * 2005-06-10 2006-12-21 Irm Llc Compounds that maintain pluripotency of embryonic stem cells
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
ES2734288T3 (es) 2007-11-28 2019-12-05 Dana Farber Cancer Inst Inc Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
EP2320907A4 (en) 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
US8575179B2 (en) * 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2011047119A1 (en) 2009-10-14 2011-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
SI3459942T1 (sl) 2012-04-24 2021-05-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP5683634B2 (ja) * 2012-11-28 2015-03-11 株式会社ショーワ 圧力緩衝装置
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
JP6576325B2 (ja) * 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
AU2014230125A1 (en) 2013-03-15 2015-10-29 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
WO2016023014A2 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
BR112019017741A2 (pt) * 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik

Also Published As

Publication number Publication date
AU2017291812B2 (en) 2023-12-14
US20210147425A1 (en) 2021-05-20
AU2017291812A1 (en) 2019-02-21
US20230234959A1 (en) 2023-07-27
US20260078126A1 (en) 2026-03-19
IL264106A (en) 2019-01-31
EP4047001A2 (en) 2022-08-24
EP3481830A1 (en) 2019-05-15
EP4047001A3 (en) 2022-11-30
KR20190075043A (ko) 2019-06-28
US10954242B2 (en) 2021-03-23
EP3481830B1 (en) 2022-02-16
CA3293479A1 (en) 2026-03-02
JP7277357B2 (ja) 2023-05-18
JP2019527682A (ja) 2019-10-03
WO2018009544A1 (en) 2018-01-11
CN110225914A (zh) 2019-09-10
ES2920823T3 (es) 2022-08-10
US20190315752A1 (en) 2019-10-17
US11725011B2 (en) 2023-08-15
US12398145B2 (en) 2025-08-26
US20200317675A9 (en) 2020-10-08
IL264106B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
US12398145B2 (en) Bicyclic urea kinase inhibitors and uses thereof
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) Macrocyclic kinase inhibitors and uses thereof
CA2955074A1 (en) Diazepane derivatives and uses thereof
CA2955077A1 (en) Dihydropteridinone derivatives and uses thereof
HK40070345A (en) Bicyclic urea kinase inhibitors and uses thereof
WO2024259178A1 (en) Glycogen synthase kinase 3 inhibitors and uses thereof
HK40008957B (en) Bicyclic urea kinase inhibitors and uses thereof
EP4601637A2 (en) Glycogen synthase kinase 3 inhibitors and uses thereof
WO2026064579A2 (en) Small molecule protein synthesis modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220406

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250724